Collaboration. [[Organization A:Organization]] will develop and design some of its ​ products (the “Products”) for manufacture using GLOBALFOUNDRIES Inc. and its subsidiaries’ (the “GF Group”) process technology as long as such GF offering meets [[Organization A:Organization]]’s product requirements. The GF Group will provide [[Organization A:Organization]] with early access to and support for GF’s ​ PDKs and related technology in line with best customer practice. In order to establish the manufacturability of the Products on the GF Group’s process technology, the parties will # work collaboratively to timely share product requirements, process technology requirements, product roadmaps and other pertinent information, and # establish a regular cadence of meetings and checkpoints to drive and track progress to mutually agreed timelines.

Collaboration Patents. ​ will ​, for preparing, filing, prosecuting (including provisional, reissue, reexamination, continuing, divisional, continuation, continuation-in-part, and substitute applications and any foreign counterparts thereof), and maintaining all Collaboration Patents and conducting any interferences and oppositions or similar proceedings relating to any such Collaboration Patents.

During the Exchange Period for a particular Collaboration Antigen, SGI has the right to substitute another Antigen in place of such Collaboration Antigen (each a “Replacement Antigen”), subject to the nomination and acceptance process described in this [Section 2.3] (each, a “Collaboration Antigen Exchange”). SGI has the right to conduct a Collaboration Antigen Exchange # up to a total ​ across the entire Research Program if the Parties have not selected, or do not select, the [[Unknown Identifier]] Antigen (e.g., SGI may replace ​ Collaboration Antigen ​, or one Collaboration Antigen ​), or # up to a total of ​ across the entire Research Program if the Parties have selected the [[Unknown Identifier]] Antigen (e.g., SGI may replace each Collaboration Antigen ​, one Collaboration Antigen ​, or one Collaboration Antigen ​and another Collaboration Antigen ​. The permitted Collaboration Antigen Exchanges will be conducted free of charge.

Future Collaboration Opportunities. During the Term, upon the written request of either Party, the Parties shall discuss potential opportunities for Allena to use the fermentation and formulation capability and capacity of Althea for future products Developed by Allena.

SGI has the right to nominate a total of up to three (3) Antigens for use in the Research Program in accordance with this Section 2.2. As of the Effective Date, the [[Unknown Identifier]] Antigen and [[Unknown Identifier]] Antigen are nominated and accepted by the Parties as the first two (2) Antigens.

Additional Collaboration Program Notice pursuant to [Section 3.1.2] with respect to the relevant Additional Collaboration Program, then after CytomX receives such Additional Collaboration Program Notice for such Additional Collaboration Program and within ​ days of Regeneron’s receipt of an invoice from CytomX, Regeneron shall pay CytomX a ​.

The Parties have agreed upon the Initial Collaboration Programs as of the Effective Date. At any time during the Program Selection Period, Regeneron shall have the option to nominate up to ​ additional Collaboration Programs, each focused on identifying Products which may include a combination of particular ​ for inclusion under this Agreement (such Collaboration Program, an “Additional Collaboration Program,” and such option, an “Additional Collaboration Program Option”).

“Collaboration Antigens” means any or all of the [[Unknown Identifier]] Antigen, the [[Unknown Identifier]] Antigen, the [[Unknown Identifier]] Antigen, or any Replacement Antigen that is included as a Collaboration Antigen in a Collaboration Antigen Exchange in accordance with [Section 2.3], as the context requires.

““Long Term Extension Study” means, with respect to each Collaboration Program, the long term extension trial for such Collaboration Program described in the Pre Exercise Development Plan and Budget.”

On a Collaboration Antigen-by-Collaboration Antigen basis, within ​ days after the first Research Candidate Selection Date for such Collaboration Antigen, the Parties will finalize a Research Plan for the Research Candidates in the Territory, which Research Plan will be approved by the JSC. An initial draft of the Research Plan for the ​ Antigen is

Research Candidates. Subject to the terms and conditions of this Agreement, on a Collaboration Antigen-by-Collaboration Antigen basis, effective as of the date on which such Collaboration Antigen becomes a “Collaboration Antigen” under this Agreement, Unum hereby grants to SGI a non-exclusive, royalty-free, fully-paid, worldwide license, under the Unum Background Technology and Unum Program IP, solely for the purpose of allowing SGI to perform any Research activities that the Parties may mutually agree that SGI will perform under this Agreement.

–Encourage teamwork and collaboration.

“4.5. Sharing of Information and Cooperation. Pursuant to [[Section 3.2, REGENXBIO]O]]O] shall identify to Clearside collaboration partners that have been granted rights by REGENXBIO related to the Development or Commercialization of Covered Products and their Affiliates and Sublicensees (collectively, “Collaboration Partners”). Clearside hereby acknowledges that it has been informed by REGENXBIO that AbbVie is a Collaboration Partner of REGENXBIO, as it relates to the Development and/or Commercialization of that certain Covered Product known as RGX-314 or other Covered Products resulting from that certain License and Collaboration Agreement, dated ​ by and between REGENXBIO and AbbVie (“AbbVie Collaboration”). Clearside agrees to engage in 3-way discussions between Clearside,

Assignment, Licence and Collaboration Agreement means the Licence and Collaboration Agreement dated ​ between Nucana Biomed Limited and Cardiff Protides Limited, as amended by the Variation Agreement dated ​ between the same parties;

SANTEN and Clearside are parties to a Collaboration Agreement (the “Original Agreement”) dated ​ (the “Effective Date”), as amended by Amendment No. 1 dated ​ (as amended, the “Collaboration Agreement”).

Merck and Ablynx now wish to expand the scope of said research collaboration by adding a maximum of 12 (twelve) further Targets to said research collaboration, on the terms and conditions set forth in this Amendment.

APPENDIX # Specified IP COLLABORATION AND LICENSE AGREEMENT

“Collaboration Agreement” means a collaboration agreement in form and substance acceptable to the Required ​ in their reasonable discretion to be entered into on or after the Closing Date between the Borrower or one or more of its Subsidiaries and a commercial health insurance payor (“Payor”) pursuant to which Payor will make unsecured loans, defer rent obligations or make other unsecured credit extensions to the Borrower or one or more of its Subsidiaries to finance the establishment of de novo facilities, including costs and expenses incurred in connection with entering into a Management Services Agreement and other similar agreements in respect of any Physician-Owned Practice which will operate such facilities (such credit extensions the “Collaboration Agreement Obligations”). The Collaboration Agreements shall provide that the Collaboration Agreement Obligations shall be subordinated to the Obligations.

Selection of Research Candidates. For each Collaboration Antigen, the JSC will select up to five (5) SGI Antibodies for inclusion in Research Candidates that specifically target such Collaboration Antigen for Research pursuant to the Research Program in accordance with the terms and conditions of this Agreement. For each Collaboration Antigen, the date upon which the JSC selects the applicable Research Candidates will be the “Research Candidate Selection Date.”